Ö¬ÖÊÌå¼°¾ÛºÏÎï×÷ΪÄÉÃ×Ò©ÎïµÄ³£ÓÃÔØÌ壬ÔÚÒ©ÎïºÏ³É·½ÃæÒÑÈ¡µÃÁ˾޴óµÄ³É¹¦£¬µ«ÔÚ°ÐÏòµÝËÍ·½Ã棬ÈÔ´æÔÚ×ÅÖî¶àÌôÕ½£¬ÄÉÃ×Ò©Îï¸ÃÈçºÎʵÏÖ°ÐÏòµÝËÍÄØ£¿
ÔÚ̸ÂÛ°ÐÏò֮ǰ£¬ÏÈÒªÁ˽âÒ»¸ö¹Ø¼üµÄÒ©Àíѧ¸ÅÄÒÔÆ÷¹Ù°ÐÏòΪÀý£ºÆ÷¹Ù°ÐÏòÒ©ÎïÊäËͲ»Êǽ«ËùÓиøÒ©¼ÁÁ¿¶¼ÊäË͵½Ä¿±êÆ÷¹Ù£¬¶øÊÇÌṩ×ã¹»µÄ¼ÁÁ¿ÒÔ´ïµ½ËùÐèµÄÉúÎïЧ¹û£¬Í¬Ê±ÏÞÖÆÍѰлýÀ۵Ķ¾ÐÔ£»¼´Ê¹´ó²¿·Ö×¢Éä¼ÁÁ¿Ã»Óе½´ïÄ¿±êÆ÷¹Ù£¬Ò²Ó¦¸Ã×ãÒÔÒýÆðÉúÀíЧӦ²¢Îª»¼ÕßÌṩÒæ´¦¡£
°ÐÏò·½Ê½·ÖÀà
ÄÉÃ×Ò©Îï°ÐÏòµÄ·½Ê½¶àÖÖ¶àÑù£¬×ܵÄÀ´½²£¬¿ÉÒÔ·ÖΪÈý´óÀࣨÈçͼ1£©¡£
¡¡¡¡Í¼1. °ÐÏò·½Ê½¹éÀàͼ
±»¶¯°ÐÏò
±»¶¯°ÐÏòÒÀÀµÓÚµ÷ÕûÄÉÃ׿ÅÁ£µÄÎïÀíÐÔÖÊ£¬Èç´óС¡¢ÐÎ×´¡¢Ó²¶ÈºÍ±íÃæµçºÉ£¬Ê¹ÆäÓë½âÆÊѧ¼°ÉúÀíѧÏà½áºÏ¡£ÀýÈ磬µ÷½ÚÄÉÃ׿ÅÁ£µÄ´óС¿ÉÒÔÈ·¶¨ÄÉÃ׿ÅÁ£´Ó²»Á¬ÐøµÄѪ¹Ü£¨Èç¸ÎÔàºÍÆ¢ÔàÖеÄѪ¹Ü£©ÍâÉøµÄÇ÷ÊÆ¡£
Ö÷¶¯°ÐÏò
Ö÷¶¯°ÐÏò°üÀ¨Óû¯Ñ§»òÉúÎïµÄ·½·¨ÐÞÊÎÄÉÃ׿ÅÁ£µÄ±íÃ棬ʹÆäÌØÒìÐÔµØÓë°ÐÆ÷¹Ù¸ß¶È±í´ïµÄÊÜÌå»òÆäËûϸ°ûÒò×ÓÏà½áºÏ¡£ÀýÈ磬Óõ¥¿Ë¡¿¹ÌåÐÞÊÎÄÉÃ׿ÅÁ££¬ÒÔʹºËËá´«µÝµ½ÄÑÒÔתȾµÄÃâÒßϸ°ûÖС£
ÄÚÔ´ÐÔ°ÐÏò
ÄÚÔ´ÐÔ°ÐÏò°üÀ¨Éè¼ÆÄÉÃ׿ÅÁ£µÄ×é³É£¬Ê¹ÆäÔÚ×¢ÉäʱÓëѪ½¬µ°°×µÄÒ»¸ö²»Í¬µÄÑÇȺ½áºÏ£¬´Ó¶ø½«ÆäÒýµ¼µ½Ä¿±êÆ÷¹Ù²¢´Ù½øÌض¨Ï¸°ûµÄÉãÈ¡¡£ÀýÈ磬²ÎÓëÌåÄÚµ¨¹Ì´¼ÔËÊäµÄµ°°×ÖÊÒѱ»Ö¤Ã÷ÊÇÖ¬ÖÊÄÉÃ׿ÅÁ£ÓÐЧµÄ¸Îϸ°û´«µÝËù±ØÐèµÄ¡£
¶Ô±È¶øÑÔ£¬±»¶¯°ÐÏòºÍÄÚÔ´ÐÔ°ÐÏòµÄÉè¼Æ¶ÈÓë¿É¿ØÐÔÏà¶Ô½ÏµÍ£¬Ö÷¶¯°ÐÏò×ÔÈ»³ÉΪÁË°ÐÏòµÝË͵ÄÑо¿½¹µã¡£ÔÚ¸ÎÍâ°ÐÏòµÄÑо¿ÖУ¬¾ÍÉæ¼°Á˽϶àµÄÖ÷¶¯ÐÔ°ÐÏò£¬±í1Ò²ÁгöÁ˶àÖÖ¸ÎÍâ¸øÒ©µÄÄÉÃ׿ÅÁ£×éºÏÎï¡£
¡¡¡¡±í1. ÓÃÓÚ¸ÎÍâ¸øÒ©µÄÄÉÃ׿ÅÁ£×éºÏÎï
°ÐÏòÐÞÊη½·¨
Ò©Îï°ÐÏò±¾ÖÊÉÏΪ¹ÙÄÜÍÅÖ®¼äµÄÏ໥×÷Ó㬼´ÄÉÃ×Ò©Îï±íÃæµÄºËÐÄ»ùÍÅÓëÊÜÌ岿λµÄ»ùÍŽøÐл¯Ñ§½áºÏ¡£ÒÔÖ¬ÖÊÄÉÃ׿ÅÁ£ÎªÀý£¬ÔØÌå×é·ÖÖеÄPEGÖ¬ÖʶàλÓÚ¿ÅÁ£±íÃæÇÒ±¾ÉíÒ×ÓÚÐÞÊΣ¬Òò´Ë£¬¿ÉÒÔÔÚPEGÖ¬ÖÊÉϼÓÔØÊÜÌ岿λµÄ½áºÏ»ùÍÅÒÔʵÏÖ°ÐÏòÄ¿µÄ¡£ÒÔÏÂÁоÙÁ˼¸ÖÖ³£¼ûµÄPEGÖ¬ÖÊÐÞÊη½·¨¡£
ÂíÀ´õ£ÑÇ°·ÐÞÊÎ
ʹÓÃDSPE-PEG2000-ÂíÀ´õ£ÑÇ°·×÷Ϊ¹¦ÄÜ»¯PEGÖ¬ÖÊ£¬Ìæ»»LNPÖÐÒ»¶¨Ä¦¶ûÁ¿µÄ¾ÛÒÒ¶þ´¼Ö¬ÖÊ£¬Í¨¹ýÆäÈ¡´úµÄôÈ»ù¶Ë°ëë×°±ËáÖ±½ÓÓëëÄżÁª£¬¿ÉÒÔÐγÉëÄ°ÐÏòµÄÄÉÃ×Á£×Ó¡£ÔÙÈçSS-31£¬Ò»ÖÖÏßÁ£Ìå°ÐÏòµÄËÄëÄ£¬¾ßÓÐÛÏ»ù£¬Ö»ÐèÓëÂíÀ´õ£ÑÇ°·±ê¼ÇµÄÖ¬ÖÊÄÉÃ׿ÅÁ£·õÓý£¬¼´¿É½øÐÐÁòõ£ÂíÀ´õ£ÑÇ°·Å¼Áª¡£
NHSÐÞÊÎ
NHSõ¥Í¨³£ÓÃÓÚ±ê¼Ç°·»ùÉúÎï·Ö×Ó¡£NHSõ¥Óë°·»ùµÄ·´Ó¦¾ßÓÐpHÒÀÀµÐÔ£¬½áºÏµÄ×î¼ÑpHÖµÓëÉúÀí»·¾³µÄpHÖµÏàͬ¡£Ê¹ÓÃDMG-PEG-COOH-NHS×÷Ϊ¹¦ÄÜ»¯PEGÖ¬ÖÊ£¬Ìæ»»LNPÖÐÒ»¶¨Ä¦¶ûÁ¿µÄ¾ÛÒÒ¶þ´¼Ö¬ÖÊ£¬Í¨¹ýÔÚC¶ËÌí¼ÓÀµ°±ËáÐÞÊÎMH42£¬²¢Í¨¹ýÆä²àÁ´µÄ²®°·Å¼Áª£¬¿ÉÒÔÐγÉëÄ°ÐÏòµÄÄÉÃ×Á£×Ó¡£
ͬÑù£¬Ðí¶à¾ßÓа·»ùµÄ¿¹ÌåºÍ°ÐÏòëÄÒ²¿Éͨ¹ý¸Ã·´Ó¦Å¼Áªµ½Ö¬ÖÊÄÉÃ׿ÅÁ£ÉÏ£ºÈéÌúµ°°×¿ÉÌØÒìÐÔ½áºÏ»î»¯µÄ½á³¦¾ÞÊÉϸ°ûÉϵÄLRP-1£¬ÊµÏÖϸ°û°ÐÏò¿¹Ñ×ÖÎÁÆ£»»¹ÓнÏΪÊìÖªµÄ³ÌÐòÐÔËÀÍöÅäÌå1µ¥¿Ë¡¿¹ÌåµÄÓ¦Óá£
°±»ùÐÞÊÎ
°±»ùÓÐÀûÓÚȩͪ·Ö×ӵĻ¯Ñ§Ñ¡ÔñÐÔ¸½×Å¡£¸Ê¶¾ÛÌÇ»¹Ô¶ËÈ©»ùÓë°±»ùôÈ»ùÐÞÊεÄÖ¬ÖÊÖ®¼äë¿Å¼Áª·´Ó¦µÄÕý½»ÌØÐÔ±£Ö¤ÁËÖ¬ÖÊÄÉÃ׿ÅÁ£±íÃæ¶àÌÇ·Ö×ÓµÄÈ¡Ïò¡£¸Ê¶¾ÛÌÇÊÜÌå°ÐÏòÖ¬ÖÊÌå¼È¿ÉÒÔ×÷Ϊ¿¹¾úÒ©ÎïµÝË͵ÄÔØÌ壬Ҳ¿ÉÒÔ×÷ΪÓÃÓÚÃâÒßÖÎÁƵÄÖØ×éÒßÃçµÄÔØÌå¡£
DBCOÐÞÊÎ
DBCO±ê¼Ç¿É´Ù½øÛÏ»ù-Ȳ·´Ó¦£¬²¢¿ÉÑ¡ÔñÐÔżÁªÓ«¹â̽Õë¡¢Ç׺ͱê¼ÇºÍϸ°û¶¾ÐÔÒ©Îï·Ö×Ó¡£ÀýÈ磬¿¹ÌåscFv-N3¿É±»ÓÐЧµØżÁªµ½DBCOÐÞÊεÄÖ¬ÖÊÄÉÃ׿ÅÁ£ÉÏ¡£Ñо¿·¢ÏÖ£¬¿¹ÌåÐÞÊεÄÖ¬ÖÊÄÉÃ׿ÅÁ£¿É´©Ô½ÑªÄÔÆÁÕÏ£¬²¢ÓÕµ¼ÄÔÌØÒìÐÔ»ýÀÛ£¬ÒÔÖÎÁÆÖÐÊàÉñ¾ÏµÍ³¼²²¡¡£
½áÂÛ£º
ÈËÌ帴ÔÓµÄÉú»¯»·¾³¸øÄÉÃ×Ò©ÎïµÄ°ÐÏòµÝËÍÖÆÔìÁËÖî¶à×èÁ¦¡£ÔÚʵ¼Ê̽Ë÷ÖУ¬±»¶¯°ÐÏò£¬Ö÷¶¯°ÐÏòºÍÄÚÔ´ÐÔ°ÐÏò£¬¿É×÷Ϊ°ÐÏòÉè¼ÆµÄÁªºÏ¹¤¾ß£¬ÔÚÑ°ÕÒ¾ø¶ÔµÄ°ÐÏòλµã¡¢ÕæʵµÄ°ÐÏò»úÀíÓë´ïµ½Êµ¼ÊµÄ°ÐÏòЧ¹ûÖ®¼äÑ°Çóƽºâ¡£Ôڴ˵±ÖУ¬Ö÷¶¯ÐÔ°ÐÏòµÄ³¢ÊÔÖµµÃÖ§³Ö£¬ÕýÈçÎÄÖÐËù½²PEGÖ¬Öʵĸ÷ÖÖÐÞÊη½Ê½£¬´óÁ¿µÄÉè¼ÆÐÔ³¢ÊÔ¶¨ÄÜÅųýÔ½À´Ô½¶àµÄ°ÐÏò¸ÉÈÅÒòËØ£¬³¯°ÐÏò»úÀíµÄÍÚ¾ò´¦¸üÉîÒ»²½¡£
²Î¿¼ÎÄÏ×£º
1. Menon, Ipshita et al. ¡°Fabrication of active targeting lipid nanoparticles: Challenges and perspectives.¡± Materials Today Advances (2022): n. pag.
2. Dilliard, S.A., Siegwart, D.J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat Rev Mater (2023).
3. Herrera-Barrera, Marco et al. ¡°Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates.¡± Science Advances 9 (2023): n. pag.
ÎÄÕ³ö×Ô£ºÏ¸°ûʵÑéÍâ°ü ÏëÁ˽â¸ü¶àÇë¹Ø×¢£ºhttp://www.do-gene.com/